BioArctic Gunilla Osswald, PhD, CEO December 4, 2017 Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice. • This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward- looking statement in this presentation, as a result of any change in BioArctic’s expectations or an y change in events, conditions or circumstances on which these forward-looking statements are based. • This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic. • The information in this presentation has not been independently verified. • No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation. 2 | BioArctic AB
Snapshot of BioArctic Company overview Investment highlights Research oriented biopharma company Highly educated personnel with proven track focusing on development of drugs in areas with record of bringing drugs from idea to market a large unmet medical need, such as Innovative portfolio of differentiated first- Alzheimer’s and Parkinson’s Disease, and generation disease modifying agents in Complete Spinal Cord Injury Alzheimer’s and Parkinson’s Disease, diagnostics Founded in 2003 by Prof. Lars Lannfelt and and pioneering Complete Spinal Cord Injury Dr. Pär Gellerfors treatment Flexible organization with approx. 25 FTEs Strategic collaborations with Eisai and AbbVie complemented with consultants and close validating highly innovative research collaborations with external partners organization and unique product candidates Strong cash balance of > SEK 1 billion Successful business model with proven track record Headquartered in Stockholm, Sweden Attractive combination of fully financed partner Listed on Nasdaq Stockholm since mid-October projects and cutting-edge, well funded, 2017 proprietary R&D pipeline with substantial market and out-licensing potential 3 | BioArctic AB
Long History of Research Achievements Within Disorders of the Central Nervous System (CNS) Background to founding Company history ▲ Scientific discoveries by Professor Lars Lannfelt laid the foundation for BioArctic ▲ The Swedish mutation demonstrated for the first time in a 2013 – Today clinical setting that amyloid-beta • BAN2401 entered Phase 2b 2010 – 2012 (A β ) peptide initiates the disease • BAN2401 Back-up candidate developed • BAN2401 entered 2007 – 2008 clinical • Extended research collaboration with • BioArctic and development for Eisai 2005 – 2006 Eisai entered AD • BAN0805 in pre-clinical development for • BioArctic and partnership on • PD Alpha- PD BAN2401 Eisai entered synuclein mAb • BioArctic and AbbVie entered 2004 – 2005 research patent filed research collaboration on PD • mAb158 isolated collaboration in • SC0806 orphan • SC0806 entered clinical development AD • New transgenic ▲ The Arctic mutation revealed that drug designation • Horizon2020 grants mouse model for in EU & US soluble aggregated forms of A β , AD developed • Vinnova grants 2003 • Vinnova grants oligomers and protofibrils, are toxic • Several AD • Listed on Nasdaq Stockholm mid-cap BioArctic founded and likely driving the disease patents filed Partnerships & research collaborations Soft money funding Successful collaborations with pharmaceutical industry validating potential value and commercialization potential for BioArctic Source: Company data. 4 | BioArctic AB
Long-standing and Extensive Partnerships Eisai collaboration and license agreements AbbVie collaboration agreement Description of agreements Milestone / royalty potential Description of agreements Milestone / royalty potential • Two previous research • Research collaboration • Total potential value of the • The total aggregated value collaborations regarding (entered Sep 2016) agreement is up to USD of the research disease modifying therapies regarding alpha-synuclein 755m incl. an up-front fee, collaborations and license for Alzheimer’s Disease that antibodies as disease option exercise fee, and agreements is approx. EUR resulted in two licenses of modifying therapies for success-based milestones 218m in signing fee and the A β oligomer/protofibril Parkinson’s Disease incl. plus tiered royalties milestones plus high single antibodies BAN2401 and BAN0805 to IND, follow-up digit royalties • BioArctic has received an BAN2401 Back-up compounds and diagnostic • BioArctic has received USD 80m up-front payment • Third research collaboration • BioArctic primarily for the research approx. EUR 47m for the ongoing regarding a new responsible for performing collaboration research collaborations, target as a disease all pre-clinical activities signing fees and milestones modifying therapy for • Option for AbbVie for Alzheimer’s Disease a license to develop and commercialize the antibodies Strategic collaborations with pharmaceutical industry validating potential value and commercialization potential for BioArctic with proven track record of delivering on research collaborations 5 | BioArctic AB
Strategic Partnerships and Cutting-Edge Proprietary R&D PRODUCT CANDIDATE INDICATION PARTNER DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 BAN2401 2) Alzheimer’s Disease (anti-A β antibody) BAN2401 Down’s Syndrome 1) (anti-A β antibody) Traumatic Brain Injury NEURODEGENERATIVE DISEASES BAN2401 Back-up Alzheimer’s Disease (anti-A β antibody) AE1501 Alzheimer’s Disease (undisclosed) AD1 D1502 Alzheimer’s Disease (undisclosed) AD1503 Alzheimer’s Disease (undisclosed) BAN0805 Parkinson’s Disease (anti-alpha-synuclein antibody) Imaging and biochemical Alzheimer’s Disease DIAGNOSTICS & biomarkers (A β ) TECHNOLOGY Imaging and biochemical Parkinson’s Disease biomarkers ( a -synuclein) BBB-technology Multiple application (blood-brain barrier) areas SC0806 SPINE Complete Spinal Cord (FGF1/device) Injury 1) Dementia and cognitive impairment associated with Down’s syndrome. Source: Company data 2) Partner with Eisai on BAN2401 for treatment of AD 6
Disease Modifying Agents and Reliable Diagnostics/Biomarkers for Neurodegenerative Diseases New therapy focus on disease pathogenesis – efforts to delay the neurodegenerative process Neurodegenerative disease therapy TODAY Neurodegenerative disease therapy TOMORROW ILLUSTRATIVE ILLUSTRATIVE Biomarkers used as diagnostic tools to identify and to monitor the therapeutic effect of disease modifying treatments Clinical diagnosis DISEASE PROGRESSION DISEASE PROGRESSION Agents that modify disease pathology Symptomatic (thereby slowing or delaying treatment the onset and disease progression) AGE AGE Significant unmet medical need to be addressed by disease modifying agents and reliable diagnostics/biomarkers 7
Protein Misfolding is Disease Causing in a Number of Neurodegenerative Diseases Including AD and PD Monomers Oligomers/Protofibrils Mature fibrils Plaque/Lewy bodies Oligomer/ Protofibril selective antibodies NEUROTOXIC FORMATIONS SOLUBLE FORMS INSOLUBLE FORMS A β P l a q u e i n A D A l p h a - s y n u c l e i n L e w y b o d i e s i n P D Source: Company information. 8 | BioArctic AB
BAN2401 – Unique Aβ Treatment Concept Selectively Targeting and Reducing Neurotoxic Oligomers/Protofibrils in AD AGGREGATION OF A β Soluble Insoluble Monomers Oligomers/protofibrils Mature fibrils Amyloid plaque COMPOUND / TARGET BAN2401 Aducanumab Gantenerumab Crenezumab Bapineuzumab Solanezumab NEUROTOXIC FORMATIONS No / low affinity High affinity Source: Binding profiles of Aducanumab, Gantenerumab, Crenezumab, Bapineuzumab and Solanezumab are Company interpretations based on information disclosed by competitors. 9 | BioArctic AB
Recommend
More recommend
